Diagnosing multiple sclerosis at a later age: More than just progressive myelopathy

Multiple Sclerosis

Volumn 16, Issue 11, 2010, Pages 1335-1340

  Bermel, Robert A ^a   Rae Grant, Alexander D ^a   Fox, Robert J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

MRI; multiple sclerosis; progressive; relapsing remitting

Indexed keywords

GADOLINIUM;

ADULT; AGED; ARTICLE; DIAGNOSTIC IMAGING; DISEASE COURSE; FEMALE; HUMAN; IMAGE ENHANCEMENT; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MYELITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; SPINAL CORD DISEASE;

AGE OF ONSET; AGED; DISABILITY EVALUATION; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; SPINAL CORD DISEASES;

EID: 78449270822     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458510377334     Document Type: Article

References (25)

1. Schumacker GA, Beebe G., Kibler RF, et al. Problems of experimental trials of therapy in multiple sclerosis: report by the Panel on the Evaluation of Experimental Trials of Therapy in Multiple Sclerosis. Ann N Y Acad Sci 1965 ; 122: 552-568.
2. Noseworthy J., Paty D., Wonnacott T., et al. Multiple sclerosis after age 50. Neurology 1983 ; 33: 1537-1544.
3. Polliack ML, Barak Y. and Achiron A. Late-onset multiple sclerosis. J Am Geriatr Soc 2001 ; 49: 168-171.
4. Kis B., Rumberg B. and Berlit P. Clinical characteristics of patients with late-onset multiple sclerosis. J Neurol 2008 ; 255: 697-702.
5. de Seze J., Delalande S., Michelin E., et al. Brain MRI in late-onset multiple sclerosis. Eur J Neurol 2005 ; 12: 241-244.
6. Hooge JP and Redekop WK Multiple sclerosis with very late onset [see comment]. Neurology 1992 ; 42: 1907-1910.
7. Martinelli V., Rodegher M., Moiola L., et al. Late onset multiple sclerosis: clinical characteristics, prognostic factors and differential diagnosis. Neurol Sci 2004 ; 25: S350-S355.
8. Azzimondi G., Stracciari A., Rinaldi R., et al. Multiple sclerosis with very late onset: report of six cases and review of the literature. Eur Neurol 1994 ; 34: 332-336.
9. Marra TR Multiple sclerosis with onset after age 60. J Am Geriatr Soc 1984 ; 32: 16-18.
10. Lyon-Caen O., Izquierdo G., Marteau R., et al. Late onset multiple sclerosis. A clinical study of 16 pathologically proven cases. Acta Neurol Scand 1985 ; 72: 56-60.
11. McDonald WI, Compston A., Edan G., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001 ; 50: 121-127.
12. Lublin FD and Reingold SC Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996 ; 46: 907-911.
13. Kidd D., Thorpe JW, Kendall BE, et al. MRI dynamics of brain and spinal cord in progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 1996 ; 60: 15-19.
14. Ovbiagele B. and Saver JL Cerebral white matter hyper-intensities on MRI: current concepts and therapeutic implications. Cerebrovasc Dis 2006 ; 22: 83-90.
15. Trojano M., Liguori M., Bosco Zimatore G., et al. Age-related disability in multiple sclerosis. Ann Neurol 2002 ; 51: 475-480.
16. Confavreux C. and Vukusic S. Age at disability milestones in multiple sclerosis. Brain 2006 ; 129: 595-605.
17. Smith ME, Eller NL, McFarland HF, et al. Age dependence of clinical and pathological manifestations of autoimmune demyelination. Implications for multiple sclerosis. Am J Pathol 1999 ; 155: 1147-1161.
18. Sim FJ, Zhao C., Penderis J. and Franklin RJM. The age-related decrease in CNS remyelination efficiency is attributable to an impairment of both oligodendrocyte progenitor recruitment and differentiation. J Neurosci 2002 ; 22: 2451-2459.
19. Filippi M., Wolinsky JS, Sormani MP, et al. Enhancement frequency decreases with increasing age in relapsing-remitting multiple sclerosis. Neurology 2001 ; 56: 422-423.
20. Wolinsky JS, Narayana PA, Noseworthy JH, et al. Linomide in relapsing and secondary progressive MS: part II: MRI results. MRI Analysis Center of the University of Texas-Houston, Health Science Center, and the North American Linomide Investigators. Neurology 2000 ; 54: 1734-1741.
21. Ingle GT, Sastre-Garriga J., Miller DH and Thompson AJ Is inflammation important in early PPMS? A longitudinal MRI study. J Neurol Neurosurg Psychiatry 2005 ; 76: 1255-1258.
22. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006 ; 354: 911-923.
23. Polman CH, O'Connor PW, Havrdova E., et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006 ; 354: 899-910.
24. Panitch H., Goodin DS, Francis G., et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE Trial. Neurology 2002 ; 59: 1496-1506.
25. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998 ; 352: 1498-1504.